<DOC>
	<DOCNO>NCT00204633</DOCNO>
	<brief_summary>The aim determine frequency RBC transfusion patient metastatic `` poor prognosis '' germ cell tumor high-dose chemotherapy ( HD-VIP , level 6 ) without Darbepoetin alfa</brief_summary>
	<brief_title>Darbepoetin Alfa Patients With `` Poor Prognosis '' Germ Cell Tumor Treated With High-Dose Chemotherapy ( HD-VIP )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Dysgerminoma</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Poor prognosis '' accord IGCCCGcriteria : Primary mediastinal tumor Gonadal/retroperitoneal germ cell tumor visceral metastasis except lung Poor marker : AFP &gt; 10.000 ng/ml betaHCG &gt; 10.000 ng/ml ( 50.000 IU/l ) andd LDH &gt; 10 x upper normal limit No previous chemotherapy Age &gt; 18 year PerformanceStatus : WHO = &lt; 2 Written informed consent Ability give inform consent Hemolysis Hematological disease insufficient erythropoiesis Patients without sufficient treatment sideropenia , folate deficiency vitamin B12 deficiency Uncontrolled arterial hypertension Treatment rhErythropoetin trial Creatinin clearance &lt; 50 ml/min Insufficient bone marrow function ( WBC count &lt; 3.000/ml platelet &lt; 100.000/Âµl ) Other major symptomatic uncontrolled illness allow complete treatment protocol exception symptom cause primary disease Second malignancy , except completely resect basal cell carcinoma skin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>